BMC Antibody and Sandbox Design
Purpose
Every other skill in this pack judges whether a business model is
GOOD. This skill judges something different: whether the client's OWN
organization will let it survive long enough to find out. A new model
often threatens existing incentives, processes, or identities inside the
company that's trying to build it — the biological metaphor
practitioners use is "corporate antibodies": the organization reacts to
something unfamiliar the way a body reacts to a mismatched transplant,
attacking it regardless of its merit. Use this once a candidate model
exists (after bmc-innovation-pattern-matching or
bmc-canvas-clarity-and-iteration) and before it's handed to the parts
of the organization that didn't design it.
Anchored in research
The "corporate antibodies" concept is independently documented under
this exact name across multiple sources: Harvard Business Review, "Get
the Corporate Antibodies on Your
Side" (2012);
and a substantial, independently-arrived-at body of corporate-innovation
writing using the same biological metaphor (Forbes, Wellspring, Idea to
Value, CIO.com). The taxonomy of antibody types in Step 2 below is this
pack's own synthesis of the recurring patterns across that literature,
not a direct reproduction of any single source's list — treat it as a
working checklist, not a citation.
Method
- Compare the new model against the existing one, block by block,
looking for conflict — not fit. For each canvas block, ask: does
this new model ask anyone in the existing organization to act against
their own current incentives, metrics, or identity? The four most
common conflict points:
- Margin conflict — the new model has structurally lower margins
than the core business, so anyone measured on blended margin has a
reason to starve it of resources or deprioritize it.
- Sales-process conflict — the new model requires a different
sales motion (self-serve vs. enterprise, subscription vs.
one-time), and the existing sales team is compensated on the old
motion — they will not sell what doesn't pay their commission
structure, regardless of stated company priority.
- Cannibalization fear — the new model could shrink revenue from
an existing, currently-successful line, and whoever owns that line's
numbers has a direct reason to slow-walk or undermine it.
- Identity/brand conflict — the new model doesn't match "who we
are" in the organization's own self-story (a premium brand entering
a low-cost segment, a B2B company going direct-to-consumer) — this
resistance is often the least visible because it's expressed as
"that's not really us" rather than a stated business objection.
- Read for early antibody activity, not just structural risk.
Signals that antibodies are already active, before the model has even
launched: sudden compliance or process objections that were never
raised for similar past initiatives; a "yes, but" response from every
functional lead consulted; resourcing requests that get acknowledged
verbally and then quietly deprioritized; the project being reframed
internally as a "pilot" or "experiment" by people who weren't asked
whether it should be one.
- Design the sandbox — don't just document the risk. Once conflict
points are named, choose protective structures matched to the
specific conflict:
- Margin conflict → a separate cost center or P&L line, so the
new model isn't blended into a metric that makes it look like a
failure by the old business's standard.
- Sales-process conflict → a dedicated sales channel or team not
carrying the old quota/commission structure — not the existing
sales team "also" selling it on the side.
- Cannibalization fear → an explicit executive mandate that
cannibalization of the old line, if it happens, is an accepted and
expected outcome, stated before launch, not litigated after the
first quarter it happens.
- Identity conflict → a distinct name, brand, or team identity
for the new initiative, so it isn't forced to inherit expectations
("but that's not how we do things") that only apply to the core
business.
- General, any conflict type → a named, senior executive sponsor
whose own performance isn't measured by the core business's
existing metrics, and a time-boxed exemption from the standard
approval/procurement/compliance gates that assume core-business
norms.
- Set an explicit integration trigger. A sandbox that never ends is
its own failure mode — decide in advance what evidence (revenue
threshold, validated demand, operational maturity) triggers folding
the initiative back into normal organizational structure, and who
makes that call.
- Name the antibody risk out loud to the sponsor, not just internally
to the design team. The point of this skill isn't to quietly work
around resistance — it's to make the risk visible enough that the
people with authority to build a sandbox actually do, before the
antibodies get there first.
What this skill does NOT do
- Doesn't guarantee the sandbox will hold — organizational politics can
overrule any structural protection; this skill reduces predictable
risk, it doesn't eliminate it.
- Doesn't replace
bmc-canvas-diagnostic-reading or
bmc-innovation-pattern-matching for judging whether the model itself
is sound — a model can be well-designed and still get killed by
antibodies, or poorly designed and survive because the sandbox is
strong; this skill only addresses the second axis.
- Doesn't apply meaningfully to a solo founder building something new
with no existing organization to conflict with — this is specifically
for a new model being introduced INTO an existing company (including
a growth-stage client adding a new line, not just large enterprises).
Refinement notes
- Which of the four conflict types have you actually seen kill an
otherwise good model in your own client work — and which sandbox
structure actually held?
- What's the earliest antibody signal you personally watch for, before
it's obvious?
- Have you ever seen a sandbox stay open too long and become its own
problem? What triggered closing it?
Continue from here
- Use after:
bmc-innovation-pattern-matching/SKILL.md or
bmc-canvas-clarity-and-iteration/SKILL.md — once a candidate model
exists.
- Use before: handing the model to functions outside the design team
(sales, finance, operations) for execution.
- This pack's shared guardrails:
../../CLAUDE.md
References
../../references/bmc-source-material-notes.md — source material background
../../references/bmc-resilience-heuristics-research.md — selection and grounding notes for this skill and its siblings
../../CLAUDE.md — this pack's shared guardrails
1---2name: bmc-antibody-and-sandbox-design3description: Reads a new business model for organizational-rejection triggers — margin conflict, sales-process conflict, cannibalization fear — inside the client's own organization, and designs a protected sandbox so internal 'antibodies' don't kill the experiment before it's tested.4---56# BMC Antibody and Sandbox Design78## Purpose910Every other skill in this pack judges whether a business model is11GOOD. This skill judges something different: whether the client's OWN12organization will let it survive long enough to find out. A new model13often threatens existing incentives, processes, or identities inside the14company that's trying to build it — the biological metaphor15practitioners use is "corporate antibodies": the organization reacts to16something unfamiliar the way a body reacts to a mismatched transplant,17attacking it regardless of its merit. Use this once a candidate model18exists (after `bmc-innovation-pattern-matching` or19`bmc-canvas-clarity-and-iteration`) and before it's handed to the parts20of the organization that didn't design it.2122## Anchored in research2324The "corporate antibodies" concept is independently documented under25this exact name across multiple sources: Harvard Business Review, ["Get26the Corporate Antibodies on Your27Side"](https://hbr.org/2012/05/get-the-corporate-antibodies-o) (2012);28and a substantial, independently-arrived-at body of corporate-innovation29writing using the same biological metaphor (Forbes, Wellspring, Idea to30Value, CIO.com). The taxonomy of antibody types in Step 2 below is this31pack's own synthesis of the recurring patterns across that literature,32not a direct reproduction of any single source's list — treat it as a33working checklist, not a citation.3435## Method36371. **Compare the new model against the existing one, block by block,38 looking for conflict — not fit.** For each canvas block, ask: does39 this new model ask anyone in the existing organization to act against40 their own current incentives, metrics, or identity? The four most41 common conflict points:42 - **Margin conflict** — the new model has structurally lower margins43 than the core business, so anyone measured on blended margin has a44 reason to starve it of resources or deprioritize it.45 - **Sales-process conflict** — the new model requires a different46 sales motion (self-serve vs. enterprise, subscription vs.47 one-time), and the existing sales team is compensated on the old48 motion — they will not sell what doesn't pay their commission49 structure, regardless of stated company priority.50 - **Cannibalization fear** — the new model could shrink revenue from51 an existing, currently-successful line, and whoever owns that line's52 numbers has a direct reason to slow-walk or undermine it.53 - **Identity/brand conflict** — the new model doesn't match "who we54 are" in the organization's own self-story (a premium brand entering55 a low-cost segment, a B2B company going direct-to-consumer) — this56 resistance is often the least visible because it's expressed as57 "that's not really us" rather than a stated business objection.582. **Read for early antibody activity, not just structural risk.**59 Signals that antibodies are already active, before the model has even60 launched: sudden compliance or process objections that were never61 raised for similar past initiatives; a "yes, but" response from every62 functional lead consulted; resourcing requests that get acknowledged63 verbally and then quietly deprioritized; the project being reframed64 internally as a "pilot" or "experiment" by people who weren't asked65 whether it should be one.663. **Design the sandbox — don't just document the risk.** Once conflict67 points are named, choose protective structures matched to the68 specific conflict:69 - **Margin conflict** → a separate cost center or P&L line, so the70 new model isn't blended into a metric that makes it look like a71 failure by the old business's standard.72 - **Sales-process conflict** → a dedicated sales channel or team not73 carrying the old quota/commission structure — not the existing74 sales team "also" selling it on the side.75 - **Cannibalization fear** → an explicit executive mandate that76 cannibalization of the old line, if it happens, is an accepted and77 expected outcome, stated before launch, not litigated after the78 first quarter it happens.79 - **Identity conflict** → a distinct name, brand, or team identity80 for the new initiative, so it isn't forced to inherit expectations81 ("but that's not how we do things") that only apply to the core82 business.83 - **General, any conflict type** → a named, senior executive sponsor84 whose own performance isn't measured by the core business's85 existing metrics, and a time-boxed exemption from the standard86 approval/procurement/compliance gates that assume core-business87 norms.884. **Set an explicit integration trigger.** A sandbox that never ends is89 its own failure mode — decide in advance what evidence (revenue90 threshold, validated demand, operational maturity) triggers folding91 the initiative back into normal organizational structure, and who92 makes that call.935. **Name the antibody risk out loud to the sponsor, not just internally94 to the design team.** The point of this skill isn't to quietly work95 around resistance — it's to make the risk visible enough that the96 people with authority to build a sandbox actually do, before the97 antibodies get there first.9899## What this skill does NOT do100101- Doesn't guarantee the sandbox will hold — organizational politics can102 overrule any structural protection; this skill reduces predictable103 risk, it doesn't eliminate it.104- Doesn't replace `bmc-canvas-diagnostic-reading` or105 `bmc-innovation-pattern-matching` for judging whether the model itself106 is sound — a model can be well-designed and still get killed by107 antibodies, or poorly designed and survive because the sandbox is108 strong; this skill only addresses the second axis.109- Doesn't apply meaningfully to a solo founder building something new110 with no existing organization to conflict with — this is specifically111 for a new model being introduced INTO an existing company (including112 a growth-stage client adding a new line, not just large enterprises).113114## Refinement notes115116- Which of the four conflict types have you actually seen kill an117 otherwise good model in your own client work — and which sandbox118 structure actually held?119- What's the earliest antibody signal you personally watch for, before120 it's obvious?121- Have you ever seen a sandbox stay open too long and become its own122 problem? What triggered closing it?123124## Continue from here125126- Use after: `bmc-innovation-pattern-matching/SKILL.md` or127 `bmc-canvas-clarity-and-iteration/SKILL.md` — once a candidate model128 exists.129- Use before: handing the model to functions outside the design team130 (sales, finance, operations) for execution.131- This pack's shared guardrails: `../../CLAUDE.md`132133## References134135- `../../references/bmc-source-material-notes.md` — source material background136- `../../references/bmc-resilience-heuristics-research.md` — selection and grounding notes for this skill and its siblings137- `../../CLAUDE.md` — this pack's shared guardrails